ELSEVIER

Focus on COVID-19 and computational immunology

IMMUNOINFORMATICS

OPEN FOR SUBMISSIONS!



The coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a serious disease that has resulted in widespread global morbidity and mortality. The immune response to SARS-CoV-2 reveals a balance between protective effects and harmful pathological reactions, hence a better understanding of the anti-viral immune response is critical for immunological treatment options. We are committed to support the global response to the COVID-19 crisis by encouraging the publication of new findings.

We are organizing a special focus on COVID-19 and computational immunology. We welcome the submission of research articles/letters, reviews, tutorial articles, perspectives, and commentaries targeting core research questions on COVID-19 at the interface between computer science, physics, mathematics, and experimental immunology. Particularly, we are encouraging back-to-back or interdependent submissions on topics that complement each other, thus leading to better discussion of trending COVID-19 science; for example, experimental and computational approaches. It is important to note that all submissions should be oriented to immunological aspects of the disease or have a substantial immunological component related to COVID-19.

General keywords: systems immunology, systems microbiology, mathematical immuno-epidemiology, database design, modelling and simulation, in silico vaccination, therapeutic options, host-viral interactions and dynamics, virus-immune system interplay.

As a reminder, **ImmunoInformatics** is waiving the article publishing charge until 31 October 2021. Manuscripts should be submitted online at: **https://www.journals.elsevier.com/immunoinformatics**. All contributions will go through the peer-review process. Contributions that are accepted will be published continuously in the journal. Submitted manuscripts should not have been published previously nor be under consideration for publication elsewhere.